Neonc Technologies Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NTHI research report →
About the company
Neonc Technologies Holdings, Inc. specializes in pioneering molecular advancements aimed at improving the targeted administration of therapies for central nervous system disorders. The company's leading pipeline candidate, NEO100, is presently undergoing Phase 2a clinical trials for the treatment of glioblastoma.
- CEO
- Amir Farrokh Heshmatpour
- IPO
- 2025
- Employees
- 8
- HQ
- Calabasas, CA, US
Price Chart
- Market Cap
- $88.38M
- P/E
- -2.28
- P/S
- 0.00
- P/B
- -7.78
- EV/EBITDA
- -2.52
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 284.28%
- ROIC
- 259.18%
- Revenue
- $39.99K · 0.00%
- Net Income
- $-62,146,210 · 0.00%
- EPS
- $-3.23 · 0.00%
- Op Income
- $-58,169,198
- FCF YoY
- 0.00%
- 52W High
- $12.99
- 52W Low
- $3.69
- 50D MA
- $4.86
- 200D MA
- $7.96
- Beta
- 0.29
- Avg Volume
- 93.50K
Get TickerSpark's AI analysis on NTHI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 24, 25 | Heshmatpour Amir F | buy | 6,000 |
| Nov 21, 25 | Heshmatpour Amir F | buy | 4,000 |
| Nov 21, 25 | Heshmatpour Amir F | buy | 20,000 |
| Nov 12, 25 | CHIANG MING-FU (ALAN) | other | 0 |
| Nov 12, 25 | CHIANG MING-FU (ALAN) | other | 0 |
| Nov 12, 25 | CHIANG MING-FU (ALAN) | other | 0 |
| Nov 12, 25 | CHIANG MING-FU (ALAN) | other | 0 |
| Nov 12, 25 | CHIANG MING-FU (ALAN) | other | 0 |
| Nov 20, 25 | Neman-Ebrahim Yousha | buy | 1,100 |
| Jun 5, 25 | Neman-Ebrahim Yousha | other | 0 |
Our NTHI coverage
Recent articles, reports, and earnings notes.
No research on NTHI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NTHI report →